JPRN-jRCT2080222135未知2 期
A phase 2, multi-center, open-label, dose-finding trial to investigate the efficacy, safety, pharmacokinetics, and pharmacodynamics of OPC-41061 in patients with chronic renal failure undergoing peritoneal dialysis
试验速览
- 阶段
- 2 期
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 80age old（—）
- 性别
- All
入选标准
- •1) Patients diagnosed with chronic renal failure
- •2) Patients who are undergoing peritoneal dialysis (continuous ambulatory peritoneal dialysis [CAPD])
- •3) Patients who, after undergoing peritoneal dialysis, received any of the following medical treatments for fluid overload [OR: hypervolemia] that had insufficient effect:
- •- Addition or increase of diuretics
- •- Increase in concentration or volume of peritoneal dialysis fluid
- •- Increase in the number of changes of peritoneal dialysis fluid
- •4) Subjects who are inpatients or who can be admitted to the trial site for the duration of the trial period
- •5) Subjects who, together with their partner, are able to practice one of the specified contraceptive methods until 4 weeks after the final trial drug administration
排除标准
- •1) Subjects with any of the following diseases, complications, or symptoms:
- •- Suspected hypovolemia
- •- Daily urine volume less than 200 mL
- •- Urination impaired due to urinary tract stricture, urinary calculus, tumor in urinary tract, or other cause
- •- Cardiac function of NYHA class 4
- •2) Subjects with any of the following medical histories:
- •- History of cerebrovascular disorder or coronary artery disease within 4 weeks prior to informed consent
- •- History of hypersensitivity or idiosyncratic reaction to benzazepine derivatives such as mozavaptan hydrochloride or benazepril hydrochloride
- •3) Subjects with any of the following abnormal laboratory values:
- •Hemoglobin lower than 9.0 g/dL, total bilirubin higher than 3.0 g/dL, ALT (GPT) or AST (GOT) 2 times the upper limit of the reference range of the trial site, serum sodium higher than the upper limit of the reference range of the trial site, serum sodium lower than 125 mEq/L, or serum potassium higher than 5.5 mEq/L
- •4) Subjects with any of the following conditions, concomitant diseases, or symptoms:
- •- defect in diaphragm
- •- hemorrhagic diathesis due to uremia
- •- suspected lactic acid metabolic disorder
- •- suspected peritonitis, peritoneal damage, peritoneal adhesion, or disorders in intraabdominal organs
- •5) Subjects who have undergone peritoneal dialysis for 8 years or longer
- •6) Subjects who are scheduled to undergo hemodialysis or concomitant use of hemodialysis, or renal transplantation
- •7) Subjects who have participated in any other clinical trial or post-marketing clinical studies within 30 days prior to informed consent
- •8) Subjects who have previously received OPC-41061
- •9) Subjects who are unable to sense thirst or who have difficulty with fluid or food intake
- •10) Female subjects who are pregnant, possibly pregnant, or nursing, or who plan to become pregnant during the trial period
- •11) Subjects otherwise judged by the investigator or subinvestigator to be inappropriate for inclusion in the trial
研究者
相似试验
未知
2 期
A phase 2, multi-center, open-label, dose-finding trial to investigate the efficacy, safety, pharmacokinetics, and pharmacodynamics of OPC-41061 in patients with chronic renal failure undergoing hemodialysis or hemodiafiltratioPatients with chronic renal failure who are undergoing hemodialysis or hemodiafiltrationJPRN-jRCT2080222101Otsuka Pharmaceutical Co., Ltd.20
进行中（未招募）
1 期
clinical study for pediatric patients with solid tumors that have come back after disappearing or that don’t respond to any treatment, designed to find the safest and most tolerable dose of nab ®-paclitaxel and to asses the preliminary efficacy of the treatment.recurrent or refractory solid tumorMedDRA version: 14.1 Level: LLT Classification code 10065147 Term: Malignant solid tumor System Organ Class: 100000004864EUCTR2013-000144-26-ITAbraxis BioScience, LLC, a wholly-owned subsidiary Celgene Corporation107
进行中（未招募）
1 期
clinical study for pediatric patients with solid tumors that have come back after disappearing or that don't respond to any treatment, designed to find the safest and most tolerable dose of nab®-paclitaxel and to asses the preliminary efficacy of the treatment.recurrent or refractory solid tumorMedDRA version: 14.1Level: LLTClassification code 10065147Term: Malignant solid tumorSystem Organ Class: 100000004864EUCTR2013-000144-26-ESAbraxis BioScience, LLC, a wholly-owned subsidiary of Celgene Corporation105
进行中（未招募）
1 期
clinical study for pediatric patients with solid tumors that have come back after disappearing or that don’t respond to any treatment, designed to find the safest and most tolerable dose of nab ®-paclitaxel and to asses the preliminary efficacy of the treatment.EUCTR2013-000144-26-FRAbraxis BioScience, LLC, a wholly-owned subsidiary of Celgene Corporation107
进行中（未招募）
1 期
clinical study for pediatric patients with solid tumors that have come back after disappearing or that don’t respond to any treatment, designed to find the safest and most tolerable dose of nab ®-paclitaxel and to asses the preliminary efficacy of the treatment.recurrent or refractory solid tumorMedDRA version: 19.0 Level: LLT Classification code 10065147 Term: Malignant solid tumor System Organ Class: 100000004864EUCTR2013-000144-26-GBCelgene Corporation107